A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Publication|Articles|July 30, 2026
- Dermatology Times, July 2026 (Vol. 47. No. 07)
- Volume 47
- Issue 07
RAD 2026: Experts Weigh In on AD Pipeline, Pediatric Care, and Personalized Treatment
Fact checked by: Georgina Carson
RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.
Advertisement
Advertisement
The
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Advertisement
Advertisement